About: Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients
Creator	Navarro, David Giménez, Estela Solano, Carlos Montoro, Juan Salavert, Miguel Sanz, Guillermo Lorenzo, Ignacio Carlos Hernández-Boluda, Juan Dolores Gómez, María Luis Piñana, José Carlos, \| Ariadna Pérez, \| Borrás, \| Eva, \| González-Barberá, María Guerreiro, \| Jaime Sanz, \|
source	Medline; PMC
abstract	BACKGROUND: There is growing evidence that community‐acquired respiratory virus (CARV) increases the risk of pulmonary invasive fungal disease (IFD) in the allogeneic hematopoietic stem cell transplantation (allo‐HSCT) setting. To date, there is a lack of knowledge regarding the risk factors (RFs), as well as the most critical period for subsequent onset of IFD after CARV infections in allo‐HSCT recipients. METHODS: In this prospective longitudinal observational CARV survey, we analyzed the effect of CARV on subsequent IFD development in 287 adult allo‐HSCT recipients diagnosed with 597 CARV episodes from December 2013 to December 2018. Multiplex PCR panel assays were used to test CARVs in respiratory specimens. FINDINGS: Twenty‐nine out of 287 allo‐HSCT recipients (10%) developed IFD after a CARV episode. The median time of IFD onset was 21 days (range, 0‐158 days) from day of the first CARV detection. Generalized estimating equation model identified 4 risk factors for IFD: ATG‐based conditioning regimen [odds ratio (OR) 2.34, 95% confidence interval (CI) 1.05‐5.2, P = .038], CARV lower respiratory tract disease (OR 10.6, 95% CI 3.7‐30.8, P < .0001), CARV infection during the first year after transplant (OR 5.34, 95% CI 1.3‐21.8, P = .014), and corticosteroids during CARV (OR 2.6, 95% CI 1.1‐6.3, P = .03). CONCLUSION: Allo‐HSCT recipients conditioned with ATG and under corticosteroid therapy at the time of CARV LRTD during the first year after transplant may require close monitoring for subsequent IFD.
has issue date	2019-09-03(xsd:dateTime)
bibo:doi	10.1111/tid.13158
bibo:pmid	31402532
has license	no-cc
sha1sum (hex)	e074fa6fb8acfc49fe8dbfd27ba0c1fce47bca03
schema:url	https://doi.org/10.1111/tid.13158
resource representing a document's title	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients
has PubMed Central identifier	PMC7169787
has PubMed identifier	31402532
schema:publication	Transpl Infect Dis
resource representing a document's body	covid:e074fa6fb8acfc49fe8dbfd27ba0c1fce47bca03#body_text
is schema:about of	named entity 'hematopoietic stem cell' named entity 'allogeneic' named entity 'fungal disease' named entity 'invasive' named entity 'allogeneic' named entity 'ONSET OF' covid:arg/e074fa6fb8acfc49fe8dbfd27ba0c1fce47bca03 named entity 'risk factors' named entity 'HSCT' named entity 'immunodeficiency' named entity 'antifungal prophylaxis' named entity 'incidence rate' named entity 'ANC' named entity 'graft-versus-host disease' named entity 'RFs' named entity 'HSCT' named entity 'voriconazole' named entity 'voriconazole' named entity 'immunocompromised' named entity 'quasi-likelihood' named entity 'ISI' named entity 'all-cause mortality' named entity 'globulin' named entity 'Treatment of Cancer' named entity 'serum levels' named entity 'HSCT' named entity 'ATG' named entity 'steroid' named entity 'micafungin' named entity 'mucosa' named entity 'HSCT' named entity 'virus' named entity 'antifungal prophylaxis' named entity 'molecular testing' named entity 'respiratory symptoms' named entity 'human parainfluenza virus' named entity 'infusion' named entity 'steroids' named entity 'posaconazole' named entity 'antifungal prophylaxis' named entity 'oseltamivir' named entity 'upper respiratory' named entity 'ISI' named entity 'community-acquired' named entity 'infectious disease' named entity 'critical period' named entity 'Mann-Whitney U test' named entity 'statistically significant' named entity 'RFs' named entity 'corticosteroids' named entity 'rituximab' named entity 'epidemiologic' named entity 'virus infection' named entity 'GvHD' named entity 'Generalized estimating equation' named entity 'response variable' named entity 'antithymocyte globulin' named entity 'RFs' named entity 'HSCT' named entity 'corticosteroids' named entity 'PCR test' named entity 'lower respiratory' named entity 'follow-up' named entity 'retrospective series' named entity 'microbiological'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software